Cited by 893Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancerCell death mechanisms and regulation

The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.

Targeting mutant p53 for efficient cancer therapy

Bykov, Vladimir J. N., Eriksson, Sofi E., Bianchi, Julie, Wiman, Klas G.·2018·Nature Reviews Cancer

DOI 10.1038/nrc.2017.109

Open this paper in CoChat — free account

Abstract

The tumour suppressor gene TP53 is the most frequently mutated gene in cancer. Wild-type p53 can suppress tumour development by multiple pathways. However, mutation of TP53 and the resultant inactivation of p53 allow evasion of tumour cell death and rapid tumour progression. The high frequency of TP53 mutation in tumours has prompted efforts to restore normal function of mutant p53 and thereby trigger tumour cell death and tumour elimination. Small molecules that can reactivate missense-mutant p53 protein have been identified by different strategies, and two compounds are being tested in clinical trials. Novel approaches for targeting TP53 nonsense mutations are also underway. This Review discusses recent progress in pharmacological reactivation of mutant p53 and highlights problems and promises with these strategies.

Integrity signals

Registry

Crossref · 10.1038/nrc.2017.109

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

1 retracted

RETRACTED: Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity
Baradaran‐Heravi, A., Niesser, J., Balgi, A. D., Choi, K., Zimmerman, C., South, A. P., Anderson, H. J., Strynadka, N. C. J., Bally, M. B., & Roberge, M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620982114 · Cited by 52
Retracted
The Protein Data Bank
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,671
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398

Flagged first, then by citations

Show all 159 references

Research works printed but not linked: 1

Shi, H., Calvez, F. L., Olivier, M. & Hainaut, P. in 25 years of p53 research ( eds Hainaut, P., Wiman, K. G. ) 293–319 (Springer, 2005).

Sorted by citations

Items 301–400 of 893

Environmentally sensitive fluorescent nucleoside analogues as probes for nucleic acid – protein interactions: molecular design and biosensing applications
Dziuba, D. (2022) · Methods and Applications in Fluorescence · doi:10.1088/2050-6120/ac7bd8 · Cited by 25
Silencing of functional p53 attenuates NAFLD by promoting HMGB1-related autophagy induction
Zhang, X., Lin, Y., Lin, S., Li, C., Gao, J., Feng, Z., Wang, J., Zhang, J., Zhang, H., Zhang, Y., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10068-4 · Cited by 24
A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients
Zhang, Y., Shi, X., Zhang, J., Chen, X., Zhang, P., Liu, A., & Zhu, T. (2021) · Scientific Reports · doi:10.1038/s41598-020-79694-0 · Cited by 23
Targeting the JAK2–STAT3–UCHL3–ENO1 axis suppresses glycolysis and enhances the sensitivity to 5-FU chemotherapy in TP53-mutant colorectal cancer
Xin, H., Zhao, Z., Guo, S., Tian, R., Ma, L., Yang, Y., Zhao, L., Wang, G., Li, B., Hu, X., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.03.041 · Cited by 25
“In recent decades, restoring p53 functionality has been an attractive strategy for developing novel anticancer drugs 18 .”
p53 suppression is essential for oncogenic SPAG5 upregulation in lung adenocarcinoma
Wang, T., Li, K., Song, H., Xu, D., Liao, Y., Jing, B., Guo, W., Hu, M., Kuang, Y., Sun, B., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.198 · Cited by 23
Biological roles of Yin Yang 2: Its implications in physiological and pathological events
Li, L., Li, Y., Meliala, I. T. S., Kasim, V., & Wu, S. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15919 · Cited by 23
Experimental anti-tumor effect of emodin in suspension – in situ hydrogels formed with self-assembling peptide
Wei, W., Tang, J., Hu, L., Feng, Y., Li, H., Yin, C., & Tang, F. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1971795 · Cited by 23
Pharmacologic approaches to amino acid depletion for cancer therapy
Wilder, C. S., Chen, Z., & DiGiovanni, J. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23349 · Cited by 23
Therapeutic bispecific antibodies against intracellular tumor antigens
Xu, G., Luo, Y., Wang, H., Wang, Y., Liu, B., & Wei, J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215699 · Cited by 23
A Water‐Stable and Red‐Emissive Radical Cation for Mutp53 Cancer Therapy
Zhou, Z., Qian, J., Liu, K., Zhang, Y., Gao, M., & Tang, B. Z. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202212671 · Cited by 23
Topoisomerase I poisons-induced autophagy: Cytoprotective, Cytotoxic or Non-protective
Elshazly, A. M., Wright, P., Xu, J., & Gewirtz, D. A. (2022) · Autophagy Reports · doi:10.1080/27694127.2022.2155904 · Cited by 24
RETRACTED ARTICLE: Downregulation of the Rho GTPase pathway abrogates resistance to ionizing radiation in wild-type p53 glioblastoma by suppressing DNA repair mechanisms
Magalhães, Y. T., Boell, V. K., Cardella, G. D., & Forti, F. L. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05812-1 · Cited by 22
“In fact, PRIMA-1 and PRIMA-1 MET (or APR-246) have been tested in several phase I/II clinical trials [45 – 47].”
Retracted
War or peace: Viruses and metastasis
Bayat, M., Golestani, S., Motlaghzadeh, S., Baghi, H. B., Lalehzadeh, A., & Nahand, J. S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189179 · Cited by 23
Roles of TP53 gene in the development of resistance to PI3K inhibitor resistances in CRISPR-Cas9-edited lung adenocarcinoma cells
Hou, J., Cao, X., Cheng, Y., & Wang, X. (2020) · Cell Biology and Toxicology · doi:10.1007/s10565-020-09523-7 · Cited by 23
Long non‐coding RNA DDX11‐AS1 promotes non‐small cell lung cancer development via regulating PI3K/AKT signalling
Feng, X., Yang, S., Zhou, S., Deng, S., & Xie, Y. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13325 · Cited by 23
APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy
Michaeli, O., Luz, I., Vatarescu, M., Manko, T., Weizman, N., Korotinsky, Y., Tsitrina, A. A., Braiman, A., Arazi, L., & Cooks, T. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06830-3 · Cited by 23
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 29
Ultrasound-Targeted Delivery Technology: A Novel Strategy for Tumor- Targeted Therapy
Du, M., Chen, Z., Chen, Y., & Li, Y. (2018) · Current Drug Targets · doi:10.2174/1389450119666180731095441 · Cited by 22
Novel Isatin-based activator of p53 transcriptional functions in tumor cells.
Mirgayazova, R., Khadiullina, R., Mingaleeva, R. N., Chasov, V. V., Gomzikova, M. O., Garanina, E. E., Rizvanov, A. A., & Bulatov, E. (2019) · PubMed Central · doi:10.22099/mbrc.2019.34179.1419 · Cited by 22
“Cellular stress leads to impaired protein-protein interaction between p53 and MDM2 as a result of phosphorylation of both proteins [1].”
Background
Porcine model elucidates function of p53 isoform in carcinogenesis and reveals novel circTP53 RNA
Niu, G., Hellmuth, I., Flisikowska, T., Pausch, H., Rieblinger, B., Carrapeiro, A. R., Schade, B., Böhm, B., Kappe, E., Fischer, K., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01686-9 · Cited by 22
“This is an important finding as epigenetic modulation has been suggested as a means of restoring wild-type p53 function, or inactivating mutant p53 activity in human cancer [47].”
Background
Mechanism, Clinical Significance, and Treatment Strategy of Warburg Effect in Hepatocellular Carcinoma
Chen, H., Wu, Q., Peng, L., Cao, T., Deng, M.-L., Liu, Y.-W., Huang, J., Hu, Y., Fu, N., Zhou, K.-B., et al. (2021) · Journal of Nanomaterials · doi:10.1155/2021/5164100 · Cited by 22
“p53 in half mutations occur in human cancers (in half of all human cancers) [31], but the wild-type p53 (WTp53) is often retained in HCC and suppressing pyruvate-driven oxidative phosphorylation by inducing PUMA [30].”
Background
p53-dependent apoptosis is essential for the antitumor effect of paclitaxel response to DNA damage in papillary thyroid carcinoma
Wu, W., Wei, T., Li, Z., & Zhu, J. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.61944 · Cited by 22
Suppression of the Proliferation of Huh7 Hepatoma Cells Involving the Downregulation of Mutant p53 Protein and Inactivation of the STAT 3 Pathway with Ailanthoidol
Tseng, T., Wang, C., Lee, Y., Shao, Y.-C., Shen, C., Lee, K., Tung, S., & Kuo, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095102 · Cited by 22
“Reactivation of the wildtype p53 function and expression or abrogation of mutant p53 protein may halt cancer progression [21].”
Background
Mapping the Potential of Microfluidics in Early Diagnosis and Personalized Treatment of Head and Neck Cancers
Pillai, S., Kwan, J. C., Yaziji, F., Yu, H., & Tran, S. D. (2023) · Cancers · doi:10.3390/cancers15153894 · Cited by 23
TRIM28 in cancer and cancer therapy
Li, K., Wang, H., Jiang, B., & Jin, X. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1431564 · Cited by 23
Analysis of Bulk RNA Sequencing Data Reveals Novel Transcription Factors Associated With Immune Infiltration Among Multiple Cancers
Liu, L., Zhao, Q., Cheng, C., Yi, J., Sun, H., Wang, Q., Quan, W., Xue, Y., Sun, L., Cong, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.644350 · Cited by 22
Partial p53 reactivation is sufficient to induce cancer regression
Klimovich, B., Meyer, L., Merle, N., Neumann, M. M., König, A. M., Ananikidis, N., Keber, C. U., Elmshäuser, S., Timofeev, O. N., & Stiewe, T. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02269-6 · Cited by 22
“Moreover, these studies demonstrated the therapeutic potential of p53 reactivation and provided critical support for the development of p53-reactivating drugs as cancer therapeutics [25, 26].”
Background
Aerobic glycolysis and tumor progression of hepatocellular carcinoma are mediated by ubiquitin of P53 K48-linked regulated by TRIM37
Ge, Y., Zhao, R., Li, B., Xiao, B., Zhou, L., & Zuo, S. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113377 · Cited by 22
Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis
Pavlakis, E., Neumann, M. M., Merle, N., Wieboldt, R., Wanzel, M., Ponath, V., von Strandmann, E. P., Elmshäuser, S., & Stiewe, T. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02785-z · Cited by 21
“To directly target the mutp53-ENTPD5-integrin axis at the level of mutp53, we investigated compounds that target the heat shock chaperone machinery, specifically HSP90 and its indispensable regulator HDAC6.”
BackgroundInfluential
P53 together with ferroptosis: a promising strategy leaving cancer cells without escape
Zhan, J., Wang, J., Liang, Y., Zeng, X., Li, E., & Wang, H. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023270 · Cited by 22
“However, TP53 mutations and the resulting inactivation of p53 lead to tumor cell death escape and rapid tumor progression [115].”
Background
Distinct TP53 Mutation Subtypes Differentially Influence Cellular Iron Metabolism
Clarke, S. L., Thompson, L. R., Dandekar, E., Srinivasan, A., & Montgomery, M. R. (2019) · Nutrients · doi:10.3390/nu11092144 · Cited by 21
The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors
Kannan, S., Partridge, A. W., Lane, D. P., & Verma, C. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235996 · Cited by 21
LncRNA miR143HG Up-Regulates p53 In Endometrial Carcinoma By Sponging miR-125a
Shi, F., Wang, T., Liu, Z., Zhang, Y., Wang, J., Zhang, K., & Su, J. (2019) · Cancer Management and Research · doi:10.2147/cmar.s222215 · Cited by 21
“Therefore, activation of p53 is considered as a promising approach for cancer therapies.(8) In”
Background
IC261, a specific inhibitor of CK1δ/ε, promotes aerobic glycolysis through p53-dependent mechanisms in colon cancer
Liu, M., Hu, Y., Lu, S., Lu, M., Li, J., Hai-min, C., Jia, H., Zhou, M., Ren, F., & Zhong, J. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.40960 · Cited by 21
“As a transcription factor and tumor-suppressor, p53 participates in the regulation of cellular biological behavior by targeting a variety of genes, including cell growth, cycle and apoptosis [47].”
In situ self-assembly of near-infrared-emitting gold nanoparticles into body-clearable 1D nanostructures with rapid lysosome escape and fast cellular excretion
He, K., Zhu, J., Gong, L., Tan, Y., Chen, H., Liang, H., Huang, B., & Liu, J. (2020) · Nano Research · doi:10.1007/s12274-020-3153-6 · Cited by 21
P53 suppresses the progression of hepatocellular carcinoma via miR‐15a by decreasing OGT expression and EZH2 stabilization
You, Z., Peng, D., Cao, Y., Zhu, Y., Yin, J., Zhang, G., & Peng, X. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16792 · Cited by 21
SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations
Gomes, A. S., Ramos, H., Gomes, S., Loureiro, J. B., Soares, J., Barcherini, V., Monti, P., Fronza, G., Oliveira, C., Domingues, L., et al. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.129440 · Cited by 21
Angiosarcoma: a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies
Luong, H. T. T., Vercammen, S., de Marco, A., de Rooster, H., & Cosma, A. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1623327 · Cited by 22
Prostate cancer aggressiveness and age: Impact of p53, BCL-2 and microvessel density
Calvocoressi, L., Uchio, E., Ko, J., Radhakrishnan, K., Aslan, M., & Concato, J. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000804 · Cited by 20
An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances
Tateo, V., Manuzzi, L., Parisi, C., Giglio, A. D., Campana, D., Pantaleo, M. A., & Lamberti, G. (2021) · Pharmaceuticals · doi:10.3390/ph14040316 · Cited by 20
High-Fidelity and Simultaneous Sensing of Endogenous Mutant and Wild p53 Proteins for Precise Cancer Diagnosis and Drug Screening
Yang, F., Li, X., Yuan, R., & Xiang, Y. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c01540 · Cited by 20
Zinc-doped Prussian blue nanoparticles for mutp53-carrying tumor ion interference and photothermal therapy
Jin, Q., Zuo, W., Lin, Q., Wu, T., Liu, C., Liu, N., Liu, J., & Zhu, X. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.07.003 · Cited by 20
Taraxasterol Inhibits Tumor Growth by Inducing Apoptosis and Modulating the Tumor Microenvironment in Non-Small Cell Lung Cancer
Lu, J., Shuai, B., Shou, Z., Guo, W., Zhou, C., Ouyang, X., Zhou, H., Li, J., Cui, J., Jiang, F., et al. (2022) · Cancers · doi:10.3390/cancers14194645 · Cited by 19
“It is widely known that targeting p53, including restoring its normal function or degradation, can trigger tumor cell death and elimination [28].”
Background
Evidence of the Beneficial Effects of Ursolic Acid against Lung Cancer
Kornel, A., Nadile, M., & Tsiani, E. (2022) · Molecules · doi:10.3390/molecules27217466 · Cited by 21
“Mutations of tumor suppressor gene p53 result in loss of function and drive carcinogenesis [19,20].”
Background
Tumor suppressor p53 mediates interleukin-6 expression to enable cancer cell evasion of genotoxic stress
Phan, T. T. T., Truong, N. V., Wu, W., Su, Y.-C., Hsu, T.-S., & Lin, L. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01638-0 · Cited by 20
“Information on primer sequences used in this study is provided in Table S2.”
Method
Paris Polyphylla -Derived Saponins Inhibit Growth of Bladder Cancer Cells by Inducing Mutant P53 Degradation While Up-Regulating CDKN1A Expression
Guo, Y., Liu, Z., Li, K., Cao, G., Sun, C., Cheng, G., Zhang, D., Peng, W., Liu, J., Qi, Y., et al. (2018) · Current Urology · doi:10.1159/000447207 · Cited by 20
Role of Thiol Reactivity for Targeting Mutant p53
Zhang, Q., Bergman, J., Wiman, K. G., & Bykov, V. J. N. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.06.013 · Cited by 20
Self-citation
Antiproliferative activity of (R)-4′-methylklavuzon on hepatocellular carcinoma cells and EpCAM+/CD133+ cancer stem cells via SIRT1 and Exportin-1 (CRM1) inhibition
Delman, M., Avcı, S. T., Akçok, İ., Kanbur, T., Erdal, E., & Çağır, A. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.024 · Cited by 20
Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer
Liao, Z., Huang, K., Kempson, I. M., Li, H., Tseng, S. ‐., & Yang, P. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.043 · Cited by 20
Estimating the predictive power of silent mutations on cancer classification and prognosis
Gutman, T., Goren, G., Efroni, O., & Tuller, T. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00229-1 · Cited by 21
Dynamic O-GlcNAcylation coordinates etoposide-triggered tumor cell pyroptosis by regulating p53 stability
Wang, J., Wang, Y., Xiao, H., Yang, W., Zuo, W., You, Z., Wu, C., & Bao, J. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108050 · Cited by 22
“%) in human tumors, leading to functional heterogeneity across cancer types (61).”
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma
Bohl, S., Schmalbrock, L. K., Bauhuf, I., Meyer, T., Dolnik, A., Szyska, M., Blätte, T. J., Knödler, S., Röhner, L., Miller, D., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003541 · Cited by 19
A pan-cancer analysis of the oncogenic role of zinc finger protein 419 in human cancer
Zhu, W., Feng, D., Shi, X., Li, D., Wei, Q., & Yang, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1042118 · Cited by 20
“Mutation of TP53 occurs in approximately 50% among all cancer types, resulting in the loss of wild-type p53 activity and unrestrained tumor progression (57).”
Background
HPV and radiosensitivity of cervical cancer: a narrative review
Huang, Y., Zou, D., Guo, M., He, M., He, H., Li, X., Zheng, Q., Li, Q., & Mao, Z. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-5930 · Cited by 19
“HPV types are divided into two categories: alpha-7 (18, 39, and 45) and alpha-9 (16, 31, 33, 52, and 58).”
Therapeutic targets in cancer treatment: Cell cycle proteins
Selvaraj, C. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.02.003 · Cited by 19
Shared Gene Targets of the ATF4 and p53 Transcriptional Networks
Baniulyte, G., Durham, S. A., Merchant, L. E., & Sammons, M. A. (2023) · Molecular and Cellular Biology · doi:10.1080/10985549.2023.2229225 · Cited by 19
Cellular Senescence in Non-Small Cell Lung Cancer
Zhu, H., Sun, J., Zhang, C., Li, P., Tan, C., Yang, M., & Zhao, G. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2812357 · Cited by 19
“One approach is to develop drugs that target specific pathways involved in cell aging, such as the TP53 pathway or the telomerase pathway [87].”
Background
Recent Advances in Nanomodulators for Augmenting Cancer Immunotherapy in Cold Tumors: Insights from Drug Delivery to Drug‐Free Strategies
Zhang, L. L., Zhu, C., Zhao, J., Scimeca, L., Dong, M., Liu, R., Jia, Y., & Xu, Z. P. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202311914 · Cited by 21
Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy
Klimovich, B., Mutlu, S., Schneikert, J., Elmshäuser, S., Klimovich, M., Nist, A., Mernberger, M., Timofeev, O. N., & Stiewe, T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910255116 · Cited by 17
“The best-known compound for reactivating mutant p53 (mutp53) is PRIMA-1 which, in the form of PRIMA-1/APR-246, is currently evaluated in clinical trials up to phase III (6).”
Background
Inactivating p53 is essential for nerve growth factor receptor to promote melanoma-initiating cell-stemmed tumorigenesis
Jiang, L., Huang, S., Wang, J., Zhang, Y., Xiong, Y., Zeng, S. X., & Lu, H. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02758-6 · Cited by 19
Interplay between HMGA and TP53 in cell cycle control along tumor progression
Costa, N. M. D., Palumbo, A., Martino, M. D., Fusco, A., Pinto, L. F. R., & Nasciutti, L. E. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03634-4 · Cited by 20
Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
Ceder, S., Eriksson, S. E., Liang, Y. Y., Cheteh, E. H., Zhang, S. M., Fujihara, K. M., Bianchi, J., Bykov, V. J. N., Abrahmsen, L., Clemons, N. J., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03988-y · Cited by 18
“The prodrug APR-246 is converted to the Michael acceptor MQ that reactivates mutant p53 and also induces oxidative stress by targeting redox regulators such as TrxR1, thioredoxin, and glutathione, leading to tumor cell death by apoptosis [45].”
BackgroundSelf-citation
Evaluation of the Prognostic Role of TP53 Gene Mutations in Prostate Cancer Outcome: A Systematic Review and Meta-Analysis
Maddah, M. M., Hedayatizadeh‐Omran, A., Moosazadeh, M., & Alizadeh‐Navaei, R. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102226 · Cited by 18
Treatment of ovarian cancer: From the past to the new era (Review)
Alrosan, K., Alrosan, A. Z., Heilat, G. B., Alrousan, A. F., Gammoh, O., Alqudah, A. M., Madae’en, S., & Alrousan, M. (2025) · Oncology Letters · doi:10.3892/ol.2025.15130 · Cited by 18
“Consequently, a potential avenue for addressing chemotherapy resistance involves reactivating mutant p53 (64).”
Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy
Song, F., Lin, S., Xu, T., Yang, C., Sharavyn, B., Naranmandura, H., Zhang, Y., & Huang, P. C. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101286 · Cited by 21
Blockade of NKG2D/NKG2D ligand interaction attenuated cardiac remodelling after myocardial infarction
Matsumoto, K., Obana, M., Kobayashi, A., Kihara, M., Shioi, G., Miyagawa, S., Maeda, M., Sakata, Y., Nakayama, H., Sawa, Y., et al. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy254 · Cited by 18
Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53 -Deficient Cancers
Goswami, M. T., VanDenBerg, K. R., Han, S., Wang, L. L., Singh, B., Weiss, T., Barlow, M., Kamberov, S., Wilder-Romans, K., Rhodes, D. R., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0144 · Cited by 18
“org Mol Cancer Res; 17(8) August 2019 1653”
BackgroundInfluential
Associations of MDM2 and MDM4 Polymorphisms with Early-Stage Breast Cancer
Bartnykaitė, A., Savukaitytė, A., Ugenskienė, R., Daukšaitė, M., Korobeinikova, E., Gudaitienė, J., & Juozaitytė, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040866 · Cited by 18
“Moreover, it is established that TP53 pathway is one of the central pathways involved in various human cancers, including breast cancer [23,44,45].”
Background
Autophagy in Viral Development and Progression of Cancer
Suares, A., Medina, M. V., & Coso, O. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.603224 · Cited by 19
“Transcription factor p53 acts as a cellular stress sensor in response to DNA damage and oncogenic stress (94) and often mutates in different types of human cancers (109).”
Background
SLC45A4 promotes glycolysis and prevents AMPK/ULK1‐induced autophagy in TP53 mutant pancreatic ductal adenocarcinoma
Chen, W., Huang, F., Huang, J., Li, Y., Peng, J., Zhuang, Y., Huang, X., Lu, L., Zhu, Z., & Zhang, S. (2021) · The Journal of Gene Medicine · doi:10.1002/jgm.3364 · Cited by 19
High Expression of PPM1D Induces Tumors Phenotypically Similar to TP53 Loss-of-Function Mutations in Mice
Milosevic, J., Fransson, S. M., Gulyás, M., Olsen, T. K., Gallo-Oller, G., Treis, D., Elfman, L. H. M., Wilhelm, M., Martinsson, T., Baryawno, N., et al. (2021) · Cancers · doi:10.3390/cancers13215493 · Cited by 19
“p53 is induced and stabilized following DNA damage through multiple posttranslational modifications, ultimately leading to transcriptional activation of p53-target genes orchestrating cell-cycle progression, DNA repair mechanisms, and apoptosis [18].”
BackgroundInfluential
QSER1 preserves the suppressive status of the pro-apoptotic genes to prevent apoptosis
Zhao, X., Fang, K., Liu, X., Yao, R., Wang, M., Li, F., Hao, S., He, J., Wang, Y., Fan, M., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01085-x · Cited by 18
“p53 prevents QSER1 from binding to its target promoters p53 deficiency confers unfavorable outcome in many cancers [29].”
Background
Comprehensive molecular characterizations of stage I–III lung adenocarcinoma with tumor spread through air spaces
Ye, R., Yu, Y., Zhao, R., Han, Y., & Lu, S. Y. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1101443 · Cited by 16
“Prevention and suppression of TP53 mutation are one of the approaches to be considered in the treatment of tumors (Bykov et al., 2018).”
Background
Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a “dominant-positive” mechanism
Walerych, D., Pruszko, M., Zyla, L., Wężyk, M., Gawęda-Walerych, K., & Żylicz, M. (2018) · Oncotarget · doi:10.18632/oncotarget.25944 · Cited by 19
“This suggests that strategies of a high overexpression of wt p53 as well as a mutant p53 conversion into wt-like conformation and activity [5, 81] are worthy efforts in finding methods to treat cancers with the accumulated mutant p53.”
Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment
Lopes, E. A., Gomes, S., Saraiva, L., & Santos, M. M. M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181116124308 · Cited by 19
Activation of TAp73 and Inhibition of TrxR by Verteporfin for Improved Cancer Therapy in TP53 Mutant Pancreatic Tumors
Acedo, P., Fernandes, A. P., & Zawacka‐Pankau, J. (2019) · Future Science OA · doi:10.4155/fsoa-2018-0082 · Cited by 18
“Despite the ongoing efforts, small molecules re-activating mutant p53 are still in clinical development [11].”
Background
Targeting transcription factors in multiple myeloma: evolving therapeutic strategies
Li, S., Vallet, S., Sacco, A., Roccaro, A. M., Lentzsch, S., & Podar, K. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1605354 · Cited by 18
“Detailed regulatory mechanisms on p53 stability have been extensively reviewed in [88].”
Background
LncRNA PLAC2 upregulates p53 to induce hepatocellular carcinoma cell apoptosis
Zheng, Y., Lv, P., Wang, S., Cai, Q., Bao, Z., & Huo, F. (2019) · Gene · doi:10.1016/j.gene.2019.143944 · Cited by 18
Metformin Enhances Nomegestrol Acetate Suppressing Growth of Endometrial Cancer Cells and May Correlate to Downregulating mTOR Activity In Vitro and In Vivo
Cao, C., Zhou, J., Xie, S., Guo, X., Li, G., Gong, Y.-J., Yang, W., Zhao, L., Zhong, R., Shao, H.-H., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133308 · Cited by 18
“TP53 can trigger cell death by apoptosis through transactivation of downstream target genes [37,38], but mutations in TP53 would promote malignant progression and lead to insensitivity of tumor cells toward chemotherapy [39].”
Background
Effects of hydroxyl radicals produced by a zinc phthalocyanine photosensitizer on tumor DNA
Yan, S., Guo, H., Su, J., Chen, J., Song, X., Huang, M., Zhang, J., & Chen, Z. (2019) · Dyes and Pigments · doi:10.1016/j.dyepig.2019.107894 · Cited by 18
Buxus alkaloid compound destabilizes mutant p53 through inhibition of the HSF1 chaperone axis
Wang, Y., Wu, W., Su, Y.-N., Ai, Z., Mou, H.-C., Wan, L.-S., Luo, Y., Qiu, M., & Zhang, J. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153187 · Cited by 17
Profiles of PD‐1, PD‐L1, PD‐L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival
Liu, J., Li, H. R., Sun, L. L., Yuan, Y., & Xing, C. (2020) · BioMed Research International · doi:10.1155/2020/2496582 · Cited by 18
“As one of the most important tumor-suppressor, TP53 mutation has long been recognized as a factor for carcinogenesis [26].”
Background
Synergetic therapy of glioma mediated by a dual delivery system loading α-mangostin and doxorubicin through cell cycle arrest and apoptotic pathways
Nie, W., Zan, X., Yu, T., Ran, M., Hong, Z., He, Y., Yang, T., Ju, Y., & Gao, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03133-1 · Cited by 18
Molecular Features and Clinical Management of Hereditary Gynecological Cancers
Ueki, A., & Hirasawa, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249504 · Cited by 17
“However, clinical trials of TP53-targeting compounds are underway [65].”
Background
Chemopreventive Effects of Dietary Isothiocyanates in Animal Models of Gastric Cancer and Synergistic Anticancer Effects With Cisplatin in Human Gastric Cancer Cells
Rabben, H.-L., Kodama, Y., Nakamura, M., Bones, A. M., Wang, T. C., Chen, D., Zhao, C., & Øverby, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.613458 · Cited by 18
Integrated analyses of microRNA-29 family and the related combination biomarkers demonstrate their widespread influence on risk, recurrence, metastasis and survival outcome in colorectal cancer
Peng, Q., Feng, Z., Shen, Y., Zhu, J., Zou, L., Shen, Y., & Zhu, Y. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0907-x · Cited by 18
Molecular Pathology of Prostate Cancer
Kulaç, İ., Roudier, M. P., & Haffner, M. C. (2024) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.08.003 · Cited by 19
A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma
Zhao, W., Nguyen, T. T., Bhagwat, A., Kumar, A., Giotti, B., Kepecs, B., Weirather, J. L., Mahadevan, N. R., Segerstolpe, Å., Dolasia, K., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01053-7 · Cited by 25
Potency and Selectivity Optimization of Tryptophanol‐Derived Oxazoloisoindolinones: Novel p53 Activators in Human Colorectal Cancer
Barcherini, V., Almeida, J., Lopes, E. A., Wang, M., Silva, D., Mori, M., Wang, S., Saraiva, L., & Santos, M. M. M. (2020) · ChemMedChem · doi:10.1002/cmdc.202000522 · Cited by 17
PCNA-associated factor (KIAA0101/PCLAF) overexpression and gene copy number alterations in hepatocellular carcinoma tissues
Tantiwetrueangdet, A., Panvichian, R., Sornmayura, P., Leelaudomlipi, S., & Macoska, J. A. (2021) · BMC Cancer · doi:10.1186/s12885-021-07994-3 · Cited by 17
Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy
Timofeev, O. N., & Stiewe, T. (2021) · Cancers · doi:10.3390/cancers13102422 · Cited by 18
“Although initial reports about the role of CTD for sequence‐specific binding were controversial, it has been shown that upon interaction with long DNA fragments, the CTD can enhance sequence‐specific DNA binding [119,120].”
Background
P53-Related Anticancer Activities of Drimia calcarata Bulb Extracts Against Lung Cancer
Laka, K., & Mbita, Z. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.876213 · Cited by 17
Intra Q-body: an antibody-based fluorogenic probe for intracellular proteins that allows live cell imaging and sorting
Dai, Y., Sato, Y., Zhu, B., Kitaguchi, T., Kimurâ, H., Ghadessy, F. J., & Ueda, H. (2022) · Chemical Science · doi:10.1039/d2sc02355e · Cited by 18
Nonsense codons suppression. An acute toxicity study of three optimized TRIDs in murine model, safety and tolerability evaluation
Corrao, F., Zizzo, M. G., Tutone, M., Melfi, R., Fiduccia, I., Carollo, P. S., Leonardo, A. D., Caldara, G., Perriera, R., Pace, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113886 · Cited by 17
Systematic analysis and case series of the diagnosis and management of trichilemmal carcinoma
Sun, J., Zhang, L., Xiao, M., Li, S., Chen, R., Li, Y., & Yang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1078272 · Cited by 19
“As a key anti-cancer protein with growth inhibitory function, p53 can regulate the cell cycle and promote cell apoptosis or senescence, thus inhibiting tumorigenesis (43).”
Background
Different applications of temperature responsive nanogels as a new drug delivery system mini review
Sam, R., Kermani, M. D., Ohadi, M., Salarpour, S., & Dehghannoudeh, G. (2023) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2023.2209796 · Cited by 17
“In addition to chemotherapy and surgery, radiotherapy, immunotherapy, and gene therapy may also be used as treatment strategies (Bykov et al. 2018).”
Background
Ubiquitin-specific protease 54 regulates GLUT1-mediated aerobic glycolysis to inhibit lung adenocarcinoma progression by modifying p53 degradation
Chen, L., Zhang, L., He, H. H., Shao, F., Yu, Z., Gao, Y., & He, J. (2024) · Oncogene · doi:10.1038/s41388-024-03047-8 · Cited by 21
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
Garziera, M., Cecchin, E., Canzonieri, V., Sorio, R., Giorda, G., Scalone, S., Mattia, E. D., Roncato, R., Gagno, S., Poletto, E., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051510 · Cited by 17
“, pharmacological reactivation of mutant p53 [12,13]—and to improve on our knowledge of the complex genomic heterogeneity of ovarian cancer.”
Background
MRI-based radiogenomics analysis for predicting genetic alterations in oncogenic signalling pathways in invasive breast carcinoma
Lin, P., LIU, W.-H., Li, X., Wan, D., Qin, H., Li, Q., Chen, G., He, Y., & Yang, H. (2020) · Clinical Radiology · doi:10.1016/j.crad.2020.02.011 · Cited by 17
Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma
Hou, S., Chen, X., Mao, L., Huang, X., Liao, H., & Tian, B. (2020) · Aging · doi:10.18632/aging.103501 · Cited by 17
“suppress tumor development by multiple pathways [13].”

Authors: Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G.
Affiliations: Karolinska Institutet (SE)
Corresponding author: Wiman, Klas G.
ORCID: Bykov, Vladimir J. N.
Eriksson, Sofi E.
Bianchi, Julie
Wiman, Klas G.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2017-12-15
Volume: 18
Issue: 2
Pages: 89-102
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc.2017.109
OpenAlex: W2772062014
Cited by: 889
References: 159
Citations by year: 2026: 43 · 2025: 70 · 2024: 100 · 2023: 132 · 2022: 126 · 2021: 150 · 2020: 129 · 2019: 88 · 2018: 49 · 2017: 1
FWCI: 7.67
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords: TP53, mutant p53, p53 reactivation, missense mutations, nonsense mutation, tumor suppressor, cancer therapy, cancer cell death, clinical trials
MeSH terms: Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Tumor Suppressor Protein p53, Cell Death, Mutant Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting mutant p53 for efficient cancer therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks